OA12099A - 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. - Google Patents

4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. Download PDF

Info

Publication number
OA12099A
OA12099A OA1200200158A OA1200200158A OA12099A OA 12099 A OA12099 A OA 12099A OA 1200200158 A OA1200200158 A OA 1200200158A OA 1200200158 A OA1200200158 A OA 1200200158A OA 12099 A OA12099 A OA 12099A
Authority
OA
OAPI
Prior art keywords
crystal
trifluoromethyl
formula
quinoline
carboxylic acid
Prior art date
Application number
OA1200200158A
Other languages
English (en)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Lyle Robinson Brostrom
Derek Lawrence Tickner
Original Assignee
Prifzer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prifzer Products Inc filed Critical Prifzer Products Inc
Publication of OA12099A publication Critical patent/OA12099A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)
OA1200200158A 1999-11-30 2000-11-14 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. OA12099A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
OA12099A true OA12099A (en) 2006-05-04

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200158A OA12099A (en) 1999-11-30 2000-11-14 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor.

Country Status (28)

Country Link
EP (1) EP1246804A1 (pt)
JP (1) JP2003515592A (pt)
KR (1) KR20020058057A (pt)
CN (1) CN1402711A (pt)
AP (1) AP2002002531A0 (pt)
AU (1) AU1048801A (pt)
BG (1) BG106854A (pt)
BR (1) BR0015836A (pt)
CA (1) CA2392979A1 (pt)
CO (1) CO5271716A1 (pt)
EA (1) EA200200510A1 (pt)
EC (1) ECSP003792A (pt)
EE (1) EE200200277A (pt)
GT (1) GT200000199A (pt)
HU (1) HUP0203521A2 (pt)
IL (1) IL149097A0 (pt)
IS (1) IS6338A (pt)
MA (1) MA26845A1 (pt)
MX (1) MXPA02005354A (pt)
NO (1) NO20022558L (pt)
OA (1) OA12099A (pt)
PA (1) PA8506301A1 (pt)
PE (1) PE20010904A1 (pt)
PL (1) PL355892A1 (pt)
TN (1) TNSN00231A1 (pt)
TR (1) TR200201446T2 (pt)
UY (1) UY26454A1 (pt)
WO (1) WO2001040190A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
GT200200170A (es) 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
MXPA04007438A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
EP1469833B1 (en) * 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
PT1533292E (pt) 2002-08-30 2007-05-31 Japan Tobacco Inc Compostos de dibenzilamina e sua utilização farmacêutica.
JP2006508077A (ja) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1622872A1 (en) * 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
EP1653927B1 (en) 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
CN1863778A (zh) 2003-10-08 2006-11-15 伊莱利利公司 用于治疗血脂异常的化合物及方法
CA2562082C (en) * 2004-04-13 2013-06-25 Merck & Co., Inc. Cetp inhibitors for the treatment and prevention of atherosclerosis
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
RU2007135224A (ru) 2005-02-24 2009-03-27 Милленниум Фармасьютикалз, Инк. (Us) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
KR102456013B1 (ko) 2014-07-30 2022-10-18 에프. 호프만-라 로슈 아게 고밀도 지질단백질(hdl)-상승 제제 또는 hdl-모방 제제에 의한 치료법에 대한 반응성을 예측하기 위한 유전 표지

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
PL355892A1 (en) 2004-05-31
BG106854A (bg) 2002-12-29
EA200200510A1 (ru) 2002-10-31
WO2001040190A1 (en) 2001-06-07
TR200201446T2 (tr) 2002-11-21
EP1246804A1 (en) 2002-10-09
NO20022558D0 (no) 2002-05-29
IS6338A (is) 2002-04-12
AU1048801A (en) 2001-06-12
JP2003515592A (ja) 2003-05-07
UY26454A1 (es) 2001-07-31
CN1402711A (zh) 2003-03-12
ECSP003792A (es) 2002-04-23
KR20020058057A (ko) 2002-07-12
IL149097A0 (en) 2002-11-10
PA8506301A1 (es) 2002-08-26
GT200000199A (es) 2002-05-23
AP2002002531A0 (en) 2002-06-30
CO5271716A1 (es) 2003-04-30
CA2392979A1 (en) 2001-06-07
MA26845A1 (fr) 2004-12-20
MXPA02005354A (es) 2002-12-11
TNSN00231A1 (fr) 2002-05-30
HUP0203521A2 (hu) 2003-02-28
PE20010904A1 (es) 2001-09-10
NO20022558L (no) 2002-05-29
BR0015836A (pt) 2002-08-06
EE200200277A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
OA12099A (en) 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor.
US6313142B1 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
TWI685486B (zh) 製備ｐｄｅ４抑制劑之方法
AU2002358585A1 (en) Acetylene derivatives having mglur 5 antagonistic activity
ZA200600156B (en) Tacrine derivatives as inhibitors of acetylcholinesterase
WO2020077024A1 (en) Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators
KR20170102204A (ko) 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법
PT87277B (pt) Processo para a preparacao de novos compostos biciclicos e composicoes farmaceuticas compreendendo os mesmos
US6063784A (en) Heteroaryloxyethylamines, method of preparation, application as medicine and pharmaceutical compositions containing them
JPH03218361A (ja) ９―アシルアミノテトラヒドロアクリジン誘導体
CA2090635A1 (en) Substituted phenylquinazoline derivatives
MXPA00011855A (en) Method for making (-)-(2r,4s)-4- [(3,5-bis- trifluoromethyl-benzyl)- methoxycarbonylamino]- 2-ethyl-6- trifluoromethyl-3,4-dihydro- 2h-quinoline- 1-carboxylic acid ethyl ester
GB2098205A (en) Indoles
WO1997005114A1 (en) Quinolone sulfonimides having leukotriene-antagonistic action
BE550426A (pt)